This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Deal: Otsuka Pharmaceuticals Pays Up for Astex

NEW YORK ( TheStreet) - Japan's Otsuka Pharmaceutical Co. Ltd. announced an $886 million deal for oncology drug specialist Astex Pharmaceuticals Inc. to bolster its pipeline before the loss of a key patent.

Otsuka,of Tokyo, said it would pay $8.50 per Astex share, a 27% premium to the shares' Tuesday close before rumors of a pending deal leaked. The stock gained 24% Wednesday.

"I hope that this acquisition of Astex will strengthen not only our cancer portfolio but also our drug discovery research in the central nervous system field, through the acquisition of Astex's fragment-based drug design technology at its Cambridge, England, research headquarters and its California clinical oncology R&D department," said Otsuka president Taro Iwamoto in a statement.

Astex, of Dublin, Calif., slipped to a second-quarter loss of $4.2 million, versus profit of $1.2 million in the same period a year earlier as it spent on research and failed to get royalties from a venture with MGI Pharma Inc. Revenue slid 17% to $16.6 million in the period.

The agreement will help Otsuka defend against the loss of its patent on Abilify, a $4.5 billion-a-year antipsychotic drug, at the end of 2014. Otsuka's last major deal came two years ago when it launched a joint venture with Copenhagen-based H. Lundbeck A/S to develop and sell five psychiatric and neuroscience products.

Lundbeck paid $200 million up front and may dole out as much as another $1.8 billion in royalties from drugs developed in the venture. They expanded the venture to include a new Alzheimer's treatment earlier this year. While two-thirds of Otsuka's sales are generated by its pharmaceuticals business, the company also has nutritional products, such as sports drinks and energy bars.

The deal is just the latest in a long string of international acquisitions by pharmaceutical companies hoping to offset expiring patents -- and Japanese companies have played a key role, bolstered by a strong yen.

Takeda Pharmaceutical Co. Ltd. in 2011 spent $12 billion on Switzerland's Nycomed International Management GmbH from a consortium of financial investors. It also spent $800 million on Philadelphia gout treatment maker URL Pharma Inc., which was also owned by financial investors.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs